These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 31371317)

  • 1. Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma.
    Lesokhin AM; Bal S; Badros AZ
    Cancer Immunol Res; 2019 Aug; 7(8):1224-1229. PubMed ID: 31371317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
    Jelinek T; Paiva B; Hajek R
    Front Immunol; 2018; 9():2431. PubMed ID: 30505301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
    Xia Y; Medeiros LJ; Young KH
    Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
    Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
    Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
    Rotte A
    J Exp Clin Cancer Res; 2019 Jun; 38(1):255. PubMed ID: 31196207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Checkpoint inhibitors in hematological malignancies.
    Ok CY; Young KH
    J Hematol Oncol; 2017 May; 10(1):103. PubMed ID: 28482851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of the PD-1 Pathway in Tumor Therapy.
    LaFleur MW; Muroyama Y; Drake CG; Sharpe AH
    J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
    Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
    Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
    Front Immunol; 2018; 9():2204. PubMed ID: 30319648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
    Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
    Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint blockade therapy.
    Wieder T; Eigentler T; Brenner E; Röcken M
    J Allergy Clin Immunol; 2018 Nov; 142(5):1403-1414. PubMed ID: 29596939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.
    Klepsch V; Hermann-Kleiter N; Baier G
    Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.